Regulation of Keratin-17 Expression and Cell Proliferation through in vivo Combination Therapy | ||
| Journal of Bioscience and Applied Research | ||
| Article 9, Volume 11, Issue 2, June 2025, Pages 470-483 PDF (1.39 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jbaar.2025.435604 | ||
| Authors | ||
| Elsayed I. Salim* ; Elham M. Yousef; Mona M. Hegazi; Mohamed Shahen | ||
| Department of Zoology, Research Lab. of Molecular Carcinogenesis, Faculty of Science, Tanta University, Tanta 31527, Egypt. | ||
| Abstract | ||
| The attention on chemoprevention of non-melanoma skin cancer (NMSC) is expanding due to its rising occurrence. In this study, a mouse model of two-stage chemically induced skin cancers was used to assess the effects of topical combination therapy with six distinct compounds: celecoxib, 1,3-diaminodihydrochloride (DAP), ginger oil, grape seed proanthocyanidins extract, Avastin, and 5-flurouracile (5-FU). Nine groups of 108 mice each were established: as a normal control, DMBA + croton oil as the cancer group, single treated groups with each drug alone, and finally a combination group with all used drugs together. At first, a topically applied single dose of 100μg of DMBA dissolved in acetone (100μL). For two weeks, mice received two applications of 1% croton oil at a volume of 100 μL/mouse. All treatments were then applied topically for 17 weeks. The current findings indicated that tumor size was affected by single-drug treatments. On the other hand, combination therapy did not reduce the mice's body weight, but it did significantly slow the growth of tumors and increase animal survival. Additionally, the combined treatment downregulated the expression of the keratin-17 (K-17) protein in all treated groups and synergistically inhibited the proliferation of tumor cells, which may be related to the halting of cell growth. | ||
| Keywords | ||
| Non-melanoma skin cancer; DMBA; croton oil; combination therapy; Keratin-17; PCNA | ||
|
Statistics Article View: 89 PDF Download: 90 |
||
